Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38

Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704) . The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057) . Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38 can be used in cancer research[1][2].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Sodium Channel; Topoisomerase

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Anti-SLC34A2(Lifastuzumab)-MC-Vc-PAB-SN38]

References & Citations

[1]Banerjee S, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29 (4) :917-923.|[2]Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16 (5) :315-337.